Tislelizumab
Tislelizumab Basic information
- Product Name:
- Tislelizumab
- Synonyms:
-
- Tislelizumab
- Research Grade Tislelizumab(DHH02206)
- Research Grade Tislelizumab
- Tislelizumab (anti-PDCD1)
- CAS:
- 1858168-59-8
- MW:
- 0
- Mol File:
- Mol File
Tislelizumab Chemical Properties
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Tislelizumab Usage And Synthesis
Uses
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma[1][2][3].
in vivo
Tislelizumab (10 mg/kg; Intraperitoneal injection; Once a week; 4 weeks) has significant antitumor effect in the B16F10 melanoma mouse model[2].
| Animal Model: | B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); once a week for 4 weeks. |
| Result: | Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition. |
References
[1] Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. DOI:10.1001/jamaoncol.2021.0366
[2] Hong Y, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021 Mar;11(3):782-792. DOI:10.1002/2211-5463.13102
[3] Zhu K, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol. 2024 Feb 22;15:1355081. DOI:10.3389/fphar.2024.1355081
TislelizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com